A Milestone for CAR T Cells
- 28 December 2017
- journal article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (26), 2593-2596
- https://doi.org/10.1056/nejme1714680
Abstract
More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed a complete response in some patients with relapsed or chemotherapy-refractory hematologic cancers for which there were no effective therapies.2-5 This personalized therapeutic approach entails the removal of peripheral-blood T cells from a patient, followed by in vitro activation, genetic modification, and expansion of . . .Keywords
This publication has 10 references indexed in Scilit:
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasThe New England Journal of Medicine, 2017
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell TherapyMolecular Therapy, 2017
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectionNature, 2017
- T-Cell Transfer Therapy Targeting Mutant KRAS in CancerNew England Journal of Medicine, 2016
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010